Jardiance Plateau & Non-Response Troubleshooting

Why Plateaus Happen: The Pharmacology in Plain Terms

Empagliflozin works by blocking the SGLT2 transporter in the S1 segment of the proximal renal tubule, forcing the kidney to excrete roughly 70 to 90 grams of glucose per day into the urine under optimal conditions. That upper ceiling on glucosuria is the first reason plateaus are biologically inevitable. Once every available SGLT2 transporter is occupied, no additional dose of empagliflozin increases glucose excretion.

The Tubular Glucose Excretion Ceiling

The maximum tubular excretion of glucose (TmG) is approximately 260 to 350 mg/min in healthy adults. At plasma glucose concentrations above the renal threshold (roughly 180 mg/dL), empagliflozin 25 mg saturates SGLT2 to its maximum pharmacologic effect. Patients whose fasting glucose is only modestly elevated will therefore experience smaller absolute glucosuria and a smaller HbA1c drop. This is not a drug failure; it is expected pharmacology.

Renal Filtration as the Rate-Limiting Step

Glucosuria depends on filtered glucose load, which equals plasma glucose multiplied by glomerular filtration rate (GFR). When eGFR falls, filtered glucose load falls, and SGLT2 inhibitors become progressively less effective for glycemic control. The 2023 ADA Standards of Care state that empagliflozin's glucose-lowering efficacy is "substantially reduced" at eGFR <45 mL/min/1.73 m² (1). Cardiorenal benefits, however, persist to eGFR <20 in the HF and CKD indications.

Adaptive Renal Compensations

A less discussed mechanism: after 3 to 6 months, the SGLT1 transporter in the S3 segment of the proximal tubule partially upregulates to reabsorb more glucose, blunting the net glucosuria. This adaptation likely explains 20 to 30% of the glycemic plateau seen in long-term observational data (2).

Diagnosing the Non-Response: A Structured Four-Axis Evaluation

Before changing a prescription, clinicians should work through four axes systematically. Skipping this step leads to premature therapy switches that may cost the patient the cardiorenal benefits empagliflozin provides independently of glycemia.

Axis 1: Confirm Adherence and Absorption

Self-reported adherence is notoriously unreliable. Ask specifically about missed doses, dose timing relative to meals, and recent changes in bowel habits (malabsorption secondary to diarrhea, bariatric anatomy, or gastroparesis reduces bioavailability). Empagliflozin's oral bioavailability is approximately 78% in healthy volunteers; significant gastrointestinal disease or rapid intestinal transit may reduce this further.

Axis 2: Check the Renal Function Trend

Pull the most recent eGFR and compare it to baseline. A drop from eGFR 65 to 48 over 18 months does not require stopping empagliflozin, but it does explain a glycemic plateau and should recalibrate HbA1c targets. The EMPEROR-Reduced trial (N=3,730) showed empagliflozin 10 mg significantly slowed eGFR decline (slope: -0.55 vs. -1.30 mL/min/1.73 m²/year) even as absolute glycemic contribution diminished at lower baseline GFR (3).

Axis 3: Screen for Pharmacodynamic Antagonists

Several drug classes blunt empagliflozin's net effect:

• NSAIDs and COX-2 inhibitors reduce renal perfusion and GFR acutely, directly cutting filtered glucose load.
• Corticosteroids (even inhaled fluticasone at high doses) raise plasma glucose by 20 to 40 mg/dL and can raise HbA1c by 0.5 to 1.0%, appearing to "override" the drug's effect.
• Thiazide diuretics at high doses reduce intravascular volume, activating the renin-angiotensin system and raising tubular glucose reabsorption.
• Atypical antipsychotics (olanzapine, clozapine) cause insulin resistance and weight gain that outpaces the drug's modest weight-loss effect.

If any of these are present, address them before escalating empagliflozin or adding agents.

Axis 4: Dietary Sodium and Carbohydrate Load

Empagliflozin's blood pressure benefit is mediated primarily through osmotic diuresis and natriuresis. A dietary recall often reveals sodium intake of 4,000 to 5,000 mg/day, which counteracts the drug's natriuretic effect almost entirely. Similarly, total carbohydrate intake above 250 g/day generates so much filtered glucose that the ceiling on glucosuria is reached quickly, blunting incremental HbA1c reduction. Reducing dietary sodium to <2,300 mg/day and total carbohydrate to 130 to 150 g/day can recover 0.3 to 0.5% of HbA1c reduction without any dose change (4).

The EMPA-REG OUTCOME Trial: What the Data Actually Say About Long-Term Response

EMPA-REG OUTCOME enrolled 7,020 patients with type 2 diabetes and established cardiovascular disease, randomizing them to empagliflozin 10 mg, 25 mg, or placebo. The primary finding, published in the New England Journal of Medicine in 2015, was a 38% relative risk reduction in cardiovascular death (3.7% vs. 5.9%; P<0.001) and a 35% reduction in hospitalization for heart failure (5).

Glycemic Response Over Time in EMPA-REG OUTCOME

HbA1c fell by approximately 0.54% with empagliflozin 10 mg at week 12, then plateaued and drifted upward modestly by week 206 as background therapy was adjusted per investigator discretion. This temporal pattern, an early dip followed by a partial return toward baseline, is the textbook empagliflozin glycemic trajectory and should not be interpreted as drug failure (5). The CV and renal benefits persisted throughout the trial regardless of HbA1c trajectory.

What This Means Clinically

A patient on empagliflozin whose HbA1c climbs from 7.1% at month 6 to 7.6% at month 24 has not experienced drug failure. The cardiovascular death reduction, the 35% slowing of eGFR decline, and the blood pressure reduction continue. The glycemic gap should be addressed by adding a complementary agent (GLP-1 RA, DPP-4i, or basal insulin), not by stopping empagliflozin.

Dose Escalation: 10 mg vs. 25 mg

The 10 mg dose is the starting point for all indications. For type 2 diabetes with inadequate glycemic response, escalation to 25 mg is appropriate at 3 months if HbA1c remains above the individual target. The incremental HbA1c benefit of dose escalation is modest: approximately 0.1 to 0.2% additional reduction. Weight loss differences between 10 mg and 25 mg are similarly small (mean difference: 0.3 kg in a pooled analysis of Phase III trials) (6).

The 25 mg dose is not approved for heart failure or CKD indications. In those settings, 10 mg is the ceiling, and the cardiorenal mechanism does not require SGLT2 saturation to the same degree as the glycemic mechanism.

The HealthRX Four-Step Plateau Decision Framework:

1. Rule out renal decline. Obtain same-day eGFR. If eGFR <45, accept reduced glycemic efficacy, retain drug for cardiorenal benefit, and add a complementary glucose-lowering agent.
2. Eliminate pharmacodynamic antagonists. Review the full medication list for NSAIDs, corticosteroids, high-dose thiazides, and atypical antipsychotics. Address each before escalating.
3. Assess dietary load. 24-hour dietary recall targeting sodium and total carbohydrate. Modify before any prescription change.
4. Escalate or combine. If steps 1 to 3 are negative and the patient has been on 10 mg for at least 12 weeks, escalate to 25 mg for glycemic indications or add a GLP-1 RA for combined glycemic and weight benefit.

Adding a GLP-1 Receptor Agonist: The Most Evidence-Based Combination

When empagliflozin alone no longer achieves glycemic or weight targets, adding a GLP-1 receptor agonist (semaglutide, liraglutide, dulaglutide) is the most evidence-supported next step per both the 2023 ADA Standards (1) and the 2023 ESC Guidelines on diabetes and cardiovascular disease.

Additive Mechanisms

Empagliflozin increases glucosuria and natriuresis. GLP-1 RAs slow gastric emptying, reduce appetite, and stimulate glucose-dependent insulin secretion. These mechanisms do not overlap, producing genuinely additive effects on HbA1c (typical combined reduction: 1.5 to 2.0%) and body weight (combined reduction: 6 to 9 kg at 52 weeks in observational cohorts).

Trial Evidence for the Combination

The DURATION-8 trial (N=695) tested exenatide extended-release plus dapagliflozin (a structurally similar SGLT2 inhibitor) against either drug alone. At 28 weeks, the combination reduced HbA1c by 2.0% vs. 1.4% for each monotherapy arm (P<0.001 for both comparisons), and body weight fell by 3.4 kg vs. 1.5 to 2.0 kg (7). No dedicated RCT of semaglutide plus empagliflozin has completed, but mechanistic similarity makes the DURATION-8 data reasonably applicable.

Safety Considerations for the Combination

The most clinically relevant risk in this combination is volume depletion. Both agents reduce intravascular volume through different routes (osmotic diuresis vs. Reduced fluid intake). Patients should be counseled to increase fluid intake to at least 2.0 to 2.5 L/day and to hold empagliflozin 24 hours before any procedure requiring fasting or bowel prep, per the FDA label (8).

Blood Pressure Non-Response on Empagliflozin

Empagliflozin produces a mean systolic blood pressure reduction of 3 to 5 mmHg in most RCTs, an effect mediated primarily by natriuresis rather than neurohormonal blockade. When this reduction is absent or reverses, three causes dominate.

Cause 1: Dietary Sodium Overconsumption

As noted above, sodium intake above 3,000 mg/day can fully counteract the natriuretic effect. A single 24-hour urine sodium measurement (target <100 mEq/day for most adults) quantifies this far more reliably than a dietary recall.

Cause 2: Concomitant Use of a Sodium-Retaining Drug

NSAIDs, corticosteroids, and some calcium channel blockers (particularly dihydropyridines at high doses) can cause rebound sodium retention that exceeds the drug's natriuretic capacity. Review the medication list specifically for these agents.

Cause 3: Reflex Renin-Angiotensin Activation

Volume loss from osmotic diuresis triggers renin release, which eventually stabilizes blood pressure through angiotensin II. Adding or optimizing an ACE inhibitor or ARB suppresses this reflex and frequently restores the blood pressure benefit. The combination of empagliflozin plus an ACEi or ARB is the standard-of-care in CKD per the 2022 KDIGO Guidelines (9).

Weight Loss Stall Specifically

Mean weight loss on empagliflozin is 2 to 3 kg at 24 weeks and typically stabilizes by 52 weeks. This is modest compared to GLP-1 RAs. Patients expecting the weight loss of semaglutide 2.4 mg (14.9% body weight at 68 weeks in STEP-1, N=1,961) (10) will consistently feel that empagliflozin is not working for weight. Managing expectations is itself a clinical intervention.

When Weight Actually Stalls Below Expected

If a patient has not reached the 2 to 3 kg expected loss after 24 weeks at appropriate dose and eGFR, check for:

• Compensatory increase in caloric intake (the drug's modest effect on appetite does not suppress eating behavior the way GLP-1 RAs do).
• Fluid retention from a new medication or worsening heart failure.
• Hypothyroidism, which blunts any weight-loss intervention.

A TSH drawn at the time of plateau evaluation is low-cost and occasionally diagnostic.

When to Add a Weight-Focused Agent

If weight loss is the primary clinical goal and 24 weeks of empagliflozin with dietary optimization has produced <2 kg loss, adding semaglutide (Ozempic 0.5 to 2.0 mg weekly for T2D, or Wegovy 2.4 mg weekly for obesity) or tirzepatide (Mounjaro/Zepbound 5 to 15 mg weekly) is appropriate per current ADA pharmacotherapy algorithms (1). Retaining empagliflozin in the regimen preserves its independent cardiorenal benefits.

Euglycemic Diabetic Ketoacidosis: The Non-Response Mimic

One scenario deserves its own section because it is frequently misread as non-response. Empagliflozin-associated euglycemic diabetic ketoacidosis (euDKA) produces fatigue, nausea, and apparent glycemic stability (plasma glucose 150 to 250 mg/dL), which can be misinterpreted as the drug working poorly on glucose while the patient just "feels off." The FDA added a black-box warning for euDKA in 2015 (8).

Risk factors include very low-carbohydrate diets, prolonged fasting, bariatric surgery, heavy alcohol use, and type 1 diabetes (off-label use). Any patient on empagliflozin who presents with nausea, vomiting, or malaise despite near-normal plasma glucose should have a point-of-care ketone measurement or a serum beta-hydroxybutyrate before the visit is closed.

Monitoring Schedule for Patients on Empagliflozin

The following schedule is consistent with 2023 ADA Standards and the KDIGO 2022 CKD Guidelines:

| Timepoint | Tests | |---|---| | Baseline | HbA1c, fasting glucose, BMP (eGFR, potassium), urine albumin-to-creatinine ratio, blood pressure | | 3 months | HbA1c, blood pressure; assess tolerability | | 6 months | HbA1c, BMP, body weight | | 12 months | Full panel: HbA1c, BMP, uACR, lipid panel, body weight | | Any plateau | eGFR trend, full medication review, dietary sodium recall, TSH if weight plateau |

Special Populations Where Plateaus Are Predictable

Type 1 Diabetes (Off-Label Use)

Empagliflozin is not FDA-approved for type 1 diabetes. The EASE-3 trial (N=730) showed 5 mg lowered HbA1c by 0.28% and reduced daily insulin dose by 10.1% but carried a 2.7% rate of euDKA at 26 weeks (11). In this population, glycemic plateau is common and the euDKA risk makes escalation particularly hazardous.

Heart Failure with Preserved Ejection Fraction (HFpEF)

EMPEROR-Preserved (N=5,988) showed empagliflozin 10 mg reduced the composite of CV death or HF hospitalization by 21% (HR 0.79; 95% CI 0.69 to 0.90) regardless of diabetes status (12). In this population, glycemic plateau is irrelevant; the clinical endpoint is symptom burden, NT-proBNP, and hospitalization rate. Titrating off empagliflozin because HbA1c has not dropped is an error in this patient group.

Older Adults (Age 75+)

Older adults have lower baseline eGFR, reduced thirst sensation, and higher fall risk from volume depletion. The glycemic benefit is attenuated; the blood pressure reduction carries a higher risk of orthostatic hypotension. The 2023 ADA/EASD consensus report on management of hyperglycemia in older adults recommends maintaining empagliflozin at 10 mg (no escalation to 25 mg) and co-prescribing adequate hydration counseling (1).

When to Stop Empagliflozin

Discontinuation is appropriate in four scenarios only:

1. EGFR falls below 20 mL/min/1.73 m² (glycemic and blood pressure indications). For HF/CKD indications, the FDA label permits continuation to eGFR <20 with caution.
2. Confirmed euDKA episode, pending full metabolic evaluation and dietary review.
3. Recurrent genitourinary infections (more than two episodes of symptomatic vulvovaginal candidiasis or urinary tract infection per year attributable to glycosuria).
4. Planned surgery or procedure requiring fasting longer than 12 hours: hold 3 to 4 days prior per the 2020 Society for Endocrinology perioperative guidance to reduce euDKA risk.

Simply having a glycemic plateau is not an indication to stop the drug when cardiorenal benefits are present.

A Note on Clinician Guidance

The 2023 ADA Standards of Care state: "For patients with type 2 diabetes and established CVD or high CV risk, CKD, or HF, an SGLT2 inhibitor with proven benefit should be used regardless of baseline HbA1c or individualized HbA1c target." This framing is critical: when a provider or patient considers stopping empagliflozin because the HbA1c response has plateaued, the decision must be weighed against losing the CV mortality benefit demonstrated in EMPA-REG OUTCOME (38% relative reduction in CV death) and the HF hospitalization benefit in EMPEROR-Preserved (5) (12).